- Home
- SKYH vs AVIR Comparison
SKYH vs AVIR Comparison
Compare SKYH & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYH | AVIR |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 318.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYH | AVIR |
|---|---|---|
| Price | $8.88 | $4.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $13.83 | $6.00 |
| AVG Volume (30 Days) | 130.1K | ★ 599.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $95.36 | N/A |
| Revenue Next Year | $69.38 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.22 | $2.46 |
| 52 Week High | $14.20 | $4.63 |
Technical Indicators
Market Signals| Indicator | SKYH | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 69.10 |
| Support Level | $8.28 | $4.04 |
| Resistance Level | $9.42 | $4.50 |
| Average True Range (ATR) | 0.38 | 0.25 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 46.40 | 96.55 |
Price Performance
Historical ComparisonAbout SKYH Sky Harbour Group Corporation
Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).